Cancer: PD1 makes waves in anticancer immunotherapy

Nature Reviews Drug Discovery

Volumn 11, Issue 8, 2012, Pages 601-

  Flemming, Alexandra ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED CELL DEATH PROTEIN 1 ANTIBODY; PROGRAMMED CELL DEATH PROTEIN LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR RESISTANCE; UNSPECIFIED SIDE EFFECT;

EID: 84864535842     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3806     Document Type: Note

References (2)

1. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012)
2. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012)